

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Chau-Jong WANG
Appl. No.: NEW
Filed: November 21, 2001
For: METHOD TO COUNTER OXIDATION OF LDL,
DECREASE TRIGLYCERIDE OR CHOLESTEROL OR
INHIBIT ATHEROSCLEROSIS USING HIBISCUS
SABDARIFFA EXTRACT

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

November 21, 2001

Sir:

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE ABSTRACT OF THE DISCLOSURE:

Please move the Abstract from the bottom of page 8 (the last page of claims) to new page 9 (a new page following the last page of claims), and replace the Abstract with the rewritten Abstract of the Disclosure located below:

--Abstract of the Disclosure

A method for countering oxidization of low density lipoproteins, reducing cholesterol or triglyceride in plasma or inhibiting atherosclerosis comprising administering an effective amount of a Hibiscus sabdariffa extract.--

IN THE SPECIFICATION:

Please add the following paragraph after the heading beginning on page 2, line 9:

--The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.--

IN THE CLAIMS:

Please amend the heading of the claims as follows:

What is claimed is:

Please amend the claims as follows:

5. (Amended) The method of claim 1, further comprising combining the said Hibiscus sabdariffa extract with a pharmaceutically acceptable carrier.

8. (Amended) The method of claim 2, wherein the administering to a human being is accomplished by a daily dose of from about 5 g to about 50 g.

Please add the following claims:

--9. The method of claim 2, further comprising combining the said Hibiscus sabdariffa extract with a pharmaceutically acceptable carrier.--

--10. The method of claim 3, further comprising combining the said Hibiscus sabdariffa extract with a pharmaceutically acceptable carrier.--

--11. The method of claim 4, further comprising combining the said Hibiscus sabdariffa extract with a pharmaceutically acceptable carrier.--

--12. The method of claim 3, wherein the administering to a human being is accomplished by a daily dose of from about 5 g to about 50 g.--

--13. The method of claim 4, wherein the administering to a human being is accomplished by a daily dose of from about 5 g to about 50 g.--

REMARKS

Claims 1-13 are pending in the present application.

The Abstract, specification, claim heading, and claims 1 and 5 have been amended, and claims 6-13 have been added. Reconsideration of the application, as amended, is respectfully requested.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the application by this Amendment.

In the event that any outstanding matters remain in this application, the Examiner is invited to contact the undersigned at (702) 205-8000 in the Washington, D.C. area.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Joe McKinney Muncy
Joe McKinney Muncy, #32,334

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

KM/asc
3854-0102P

Attachments

(Rev. 09/27/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Abstract of the Disclosure:

The Abstract of the Disclosure has been moved from the bottom of page 8 (the last page of claims) to new page 9 (a new page following the last page of claims), and has been amended as follows:

--Abstract of the Disclosure

A method for countering oxidization of low density lipoproteins, reducing cholesterol or triglyceride in plasma or inhibiting atherosclerosis comprising administering an effective amount of a Hibiscus sabdariffa extract.--

IN THE SPECIFICATION

A paragraph has been added after the heading beginning on page 2, line 9.

IN THE CLAIMS:

The heading of the claims has been amended as follows:

[Method to counter oxidation of LDL, decrease triglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract

Claims]

What is claimed is:

The claims have been amended as follows:

5. (Amended) The method of claim 1[, 2, 3 or 4 wherein], further comprising combining the said Hibiscus sabdariffa extract with a pharmaceutically acceptable carrier.

8. (Amended) The method of claim 2[, 3 or 4], wherein the administering to a human being is accomplished by a daily dose of from about 5 g to about 50 g.

Claims 9-13 have been added.

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Chau-Jong WANG
Appl. No.: NEW
Filed: November 21, 2001
For: METHOD TO COUNTER OXIDATION OF LDL,
DECREASE TRIGLYCERIDE OR CHOLESTEROL OR
INHIBIT ATHEROSCHLEROSIS USING HIBISCUS
SABDARIFFA EXTRACT

LETTER TO THE OFFICIAL DRAFTSPERSON

Assistant Commissioner for Patents
Washington, DC 20231

November 21, 2001

Sir:

Subject to the approval of the Examiner, Figs. 1 and 2 will be amended to include the figure numbers indicated in red on the attached photocopies thereof.

In particular, Fig. 1 will be labeled as two separate figures, Fig. 1A and 1B. Fig. 2 will also be labeled as two separate figures, Fig. 2A and 2B.

It is respectfully requested that these proposed drawing corrections be approved.

In addition, attached herewith are two (2) sheets of corrected formal drawings having these corrections included therein. It is respectfully requested that these formal drawings be approved and that the Official Draftsperson acknowledge approval of all of these drawings.

Attorney Docket No. 3854-0102P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Joe McKinney Muncy
Joe McKinney Muncy, #32,334


P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

KM/asc
3854-0102P

Attachments

09094430
0546860


4



1 2 3 4 5 6 7 8 9

FIG 1A

B



CuSO ₄	-	+	+	+	+	-	-	-	-	10 μM
SNP	-	-	-	-	-	+	+	+	+	100 m M
HSE	-	-	0.5	1.0	2.0	-	0.5	1.0	2.0	mg/ml

FIG. 1B




FIG 2A





FIG 2B



1 2 3 4 5 6 7 8 9

FIG. 1A





FIG. 1B



1 2 3 4 5 6 7 8 9

FIG. 2A




FIG. 2B